Dow Up0.33% Nasdaq Up0.26%

Rexahn Pharmaceuticals, Inc. (RNN)

0.71 Down 0.00(0.56%) 1:05PM EST
ProfileGet Profile for:
Rexahn Pharmaceuticals, Inc.
15245 Shady Grove Road
Suite 455
Rockville, MD 20850
United States - Map
Phone: 240-268-5300
Fax: 240-268-5310

Index Membership:N/A
Full Time Employees:16

Business Summary 

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer. The company has three clinical stage oncology candidates: Archexin, RX-3117, and SupinoxinTM (RX-5902), as well as a pipeline of preclinical compounds to treat multiple types of cancer. Rexahn has also developed proprietary drug discovery platform technologies in the areas of Nano-Polymer-Drug Conjugate Systems (NPDCS), nano-medicines, 3D-GOLD, and TIMES. The company is based in Rockville, Maryland.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Rexahn Pharmaceuticals, Inc.

Key Executives 
Dr. Chang H. Ahn Ph.D., 62
Founder, Chairman and Chief Scientist
Dr. Peter D. Suzdak Ph.D., 55
Chief Exec. Officer and Director
Mr. Rakesh Soni , 58
Pres and Chief Operating Officer
Dr. Tae Heum Jeong D. Mgt., 43
Chief Financial Officer, Principal Accounting Officer, Sr. VP and Sec.
Dr. Stephen M. Stahl M.D., Ph.D.,
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders